AvKARE Recalls Dutasteride Capsules Due to Impurity Specification Failures
AvKARE Inc. is recalling specific lots of Dutasteride Capsules, 0.5 mg, because they failed impurity and degradation specifications.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text identifies the recall as FDA Class II. Per the rubric, FDA Class II recalls are classified as Severe (Score 4), particularly when involving chemical specification failures that may cause adverse health consequences.
Plain-English summary
AvKARE Inc. is voluntarily recalling 3,989 cartons of Dutasteride Capsules, 0.5 mg, 30 Capsules (6 X 5) Unit Dose per carton. The affected product is prescription-only and was distributed nationwide in the USA. The recall involves three specific lots: 25246 (Exp. 02/2021), 24532 (Exp. 10/2020), and 23647 (Exp. 06/2020).
The recall was initiated because the product failed impurities and degradation specifications, specifically showing high out-of-specification results for related compounds. The U.S. Food and Drug Administration has classified this as a Class II recall, indicating a situation where use of, or exposure to, the violative product may cause temporary or medically reversible adverse health consequences.
Patients and healthcare providers should check their inventory for the specific NDC 50268-282-13 and the lot numbers listed above. If the product matches these details, it should be discontinued and returned to the distributor or manufacturer for credit. Consumers should consult their healthcare provider for alternative treatment options if they are currently using this medication.
The recalled product
- Product
- Dutasteride Capsules, 0.5 mg, 30 Capsules (6 X 5) Unit Dose per carton, Rx Only, Manufactured for: AvKARE, Inc., Pulaski, TN 38478, NDC 50268-282-13.
- Manufacturer
- AVKARE Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 3,989
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lots: 25246
- Exp. 02/2021
- 24532
- Exp. 10/2020
- 23647
- Exp. 06/2020
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · AVKARE Inc.
See all →- ModerateLamotrigine Tablets Recalled for Label Strength Error
FDA (Drugs) · 2022-08-17
- ModeratePhytonadione Tablets 5 mg Recalled Due to Failed Impurities Specification
FDA (Drugs) · 2021-06-23
- ModerateAvKARE Recalls Sildenafil Tablets Due to Packaging Mix-Up with Trazodone
FDA (Drugs) · 2020-12-23
- CriticalAvKare Recalls Trazodone Hydrochloride Tablets Due to Sildenafil Packaging Mix-Up
FDA (Drugs) · 2020-12-23
- ModerateAvKARE Recalls Mesalamine Tablets for Failed Dissolution Specifications
FDA (Drugs) · 2020-11-18
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17